Skip to main content

Advertisement

SpringerLink
Log in

A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Cardiovascular diseases are the leading cause of death in the USA. Moreover, hypertension affects approximately 78 million people in the USA and is a major modifiable risk factor. Therefore, elevated blood pressure is listed as the primary contributory cause of death in 15 % of the 2.4 million deaths in 2009. Nonetheless, 44 % of the hypertensive population in the USA did not have it under control in 2014. Hypertension cost was averaged to be 40–50 billion dollars yearly including medications and services and currently rising. New hypertension guidelines recommend treating individuals between ages 35 and 74 with different stages of hypertension. Furthermore, individuals with existing co-morbidities such as chronic kidney disease and diabetes should have increased medication adherence and different blood pressure goal compared to those without co-morbidities. Studies utilizing quality-adjusted life-years (QUALYs) were conducted to asses the cost-effectiveness of treating previously untreated adults with hypertension. On average, treating adults between ages 35 to 74 years could prevent about 50,000 and 13,000 cardiovascular events and deaths, respectively. Overall, treating stage 1 and 2 hypertension adults including emphasis on medication adherence could be effective and cost saving. The purpose of this article is to review different methods and assess cost-effectiveness for hypertension therapy based on the 2014 guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.

    Article  CAS  PubMed  Google Scholar 

  2. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. This article talks about the 2014 guidelines for hypertension, including diagnosis, co-morbidities, treatment options, and goals.

    Article  CAS  PubMed  Google Scholar 

  3. Franklin SS, Wachtell K, Papademetriou V, Olsen MH, Devereux RB, Fyhrquist F, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension. 2005;46(3):492–9.

    Article  CAS  PubMed  Google Scholar 

  4. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

    Article  PubMed  Google Scholar 

  5. Centers for Disease, C. and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010. MMWR Morb Mortal Wkly Rep. 2012;61:703–9.

    Google Scholar 

  6. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.

    Article  CAS  PubMed  Google Scholar 

  7. Staessen JA, Birkenhager WH, Fagard R. Implications of the Systolic Hypertension in Europe (Syst-Eur) Trial for clinical practice. Nephrol Dial Transplant. 1997;12(11):2220–2.

    Article  CAS  PubMed  Google Scholar 

  8. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56(2):196–202.

    Article  CAS  PubMed  Google Scholar 

  9. Group JS. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31(12):2115–27.

    Article  Google Scholar 

  10. Antikainen R, Tuomilehto J, Thijs L, Vanhanen H, Sarti C, Birkenhäger W, et al. Therapy in old patients with isolated systolic hypertension: fourth progress report on the Syst-Eur trial. J Hum Hypertens. 1997;11(5):263–9.

    Article  CAS  PubMed  Google Scholar 

  11. Officers A, A.C.R.G.T.A. Coordinators for the, and T. Lipid-Lowering Treatment to Prevent Heart Attack. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.

    Article  Google Scholar 

  12. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48.

    Article  CAS  PubMed  Google Scholar 

  13. Ezzati M et al. Comparative quantification of mortality and burden of disease attributable to selected risk factors. In Global Burden of Disease and Risk Factors. Lopez AD et al., Editors. 2006: Washington (DC).

  14. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362(7):590–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. This study focuses on the general burden for all cardiovascular disease and the high cost that it represents nowadays with projections to 2030.

    Article  PubMed  Google Scholar 

  16. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.

    Article  PubMed  Google Scholar 

  17. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372(5):447–55. This study uses the cardiovascular disease policy to project the 2014 guidelines of hypertension 10 years into the future and possible benefits at the time of practicing cost-effective medicine.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jonsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B, et al. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens. 2005;23(7):1425–31.

    Article  PubMed  Google Scholar 

  19. Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Antihypertensive and G. Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42(3):239–46.

    Article  Google Scholar 

  21. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.

    Article  CAS  PubMed  Google Scholar 

  22. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–6.

    Article  CAS  PubMed  Google Scholar 

  23. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16.

    Article  PubMed  Google Scholar 

  24. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Science Center at El Paso, 4800 Alberta Ave, El Paso, TX, 79905, USA

    Priyanka Wani & Carlos Blanco-Garcia

Authors
  1. Priyanka Wani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Blanco-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priyanka Wani.

Ethics declarations

Conflict of Interest

Priyanka Wani and Carlos Blanco-Garcia declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wani, P., Blanco-Garcia, C. A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines. Curr Cardiol Rep 18, 24 (2016). https://doi.org/10.1007/s11886-016-0703-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0703-3

Keywords

Search

Navigation